Because echocardiography was not performed routinely to assess the ejection fraction in these cardiovascular safety trials, any differential effect of SGLT2 inhibitors on patients with HF with preserved or reduced ejection fraction merits further study. The gene discussed is SLC5A2; the disease is hydrops fetalis.